Recombinant Chicken ALDH1A3

• Cat.No.: ALDH1A3-6235C
• Product Overview: Recombinant Chicken ALDH1A3 full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Chicken
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 oC for short term. For long term storage, store it at -20 oC～-80 oC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: ALDH1A3 aldehyde dehydrogenase 1 family, member A3 [ Gallus gallus (chicken) ]
• Official Symbol: ALDH1A3
• Gene ID: 395389
• Protein Refseq: NP_990000
• UniProt ID: Q9DD46

Reviews

04/27/2022

The combination of high-quality ALDH1A3 protein and excellent technical support provided by the manufacturer makes them the ideal choice for my research.

11/05/2020

The manufacturer's extensive experience and expertise in the field of ALDH1A3 protein research make them a trusted partner.

10/14/2016

The manufacturer's commitment to providing excellent technical support is highly valuable.

Q&As

How is ALDH1A3 protein clinically relevant?

ALDH1A3 has been implicated in cancer stem cell maintenance and differentiation, making it a potential target for cancer therapy.

Can ALDH1A3 be a potential therapeutic target beyond cancer?

ALDH1A3 has implications beyond cancer, and its role in retinoic acid metabolism suggests potential therapeutic applications in developmental disorders and other diseases.

How does ALDH1A3 contribute to the epithelial-mesenchymal transition (EMT) process?

ALDH1A3 is involved in the EMT process, a crucial step in cancer metastasis, highlighting its significance in tumor invasion and spread.

In which cancers is ALDH1A3 protein overexpressed?

ALDH1A3 overexpression has been observed in various cancers, including breast, lung, ovarian, and pancreatic cancers.

Are there any ongoing clinical trials targeting ALDH1A3?

Clinical trials are exploring the therapeutic potential of targeting ALDH1A3, evaluating the safety and efficacy of novel drugs in cancer patients.